Abstract

Background Short-term intensive insulin therapy induces long-term glycemic remission in half of patients with newly diagnosed type 2 diabetes. The concomitant hypoglycemia needs further analysis. Methods We collected data from three randomized trials conducted with the same inclusion and exclusion criteria at our institution from 2002 to 2015. Continuous subcutaneous insulin infusion (CSII) was provided to achieve the glycemic goals within a week and then maintained for 14 days. Hypoglycemia episodes during short-term treatment and the one-year drug-free glycemic remission were observed. Results A total of 244 patients were included. The per day episode of mild hypoglycemia (3.0-3.9 mmol/L) was higher in the remission group than in the nonremission group (0.26 ± 0.20 vs. 0.18 ± 0.21, P = 0.005). However, a moderate hypoglycemia episode (<3.0 mmol/L) per day was insignificantly lower in the remission group (0.02 ± 0.04 vs. 0.03 ± 0.04, P = 0.005). However, a moderate hypoglycemia episode (<3.0 mmol/L) per day was insignificantly lower in the remission group (0.02 ± 0.04 vs. 0.03 ± 0.04, P = 0.005). However, a moderate hypoglycemia episode (<3.0 mmol/L) per day was insignificantly lower in the remission group (0.02 ± 0.04 vs. 0.03 ± 0.04, P = 0.005). However, a moderate hypoglycemia episode (<3.0 mmol/L) per day was insignificantly lower in the remission group (0.02 ± 0.04 vs. 0.03 ± 0.04, Conclusions Mild hypoglycemic episodes during the continuing insulin dose reduction period indicate a long-term drug-free euglycemic remission in patients with newly diagnosed type 2 diabetes. However, the insulin dosage should be reduced even more quickly in the future treatment to decrease the potential harms.

Highlights

  • Diabetes is characterized by a progressive deterioration of βcell function and reduction in insulin sensitivity [1, 2]

  • Hypoglycemia is classified into three levels based on the standard for hypoglycemia suggested by the recent American Diabetes Association (ADA) guideline [13], i.e., hypoglycemia alert value, clinically significant hypoglycemia, and severe Journal of Diabetes Research hypoglycemia

  • We analyzed the influence of mild hypoglycemia with nadir glucose levels of 3.0-3.9 mmol/L and moderate hypoglycemia (

Read more

Summary

Introduction

Diabetes is characterized by a progressive deterioration of βcell function and reduction in insulin sensitivity [1, 2]. Around half of the patients with newly diagnosed type 2 diabetes responded to CSII therapy and attained a long-term drug-free glycemic remission in our series of studies [7,8,9]. Short-term intensive insulin therapy induces long-term glycemic remission in half of patients with newly diagnosed type 2 diabetes. Hypoglycemia episodes during short-term treatment and the one-year drug-free glycemic remission were observed. The per day episode of mild hypoglycemia (3.0-3.9 mmol/L) was higher in the remission group than in the nonremission group (0:26 ± 0:20 vs 0:18 ± 0:21, P = 0:005). Logistic regression analysis showed that mild hypoglycemic episodes during short-term CSII treatment were independently related to a long-term glycemic remission (OR = 2:18, 95% CI 1.02~4.70). Mild hypoglycemic episodes during the continuing insulin dose reduction period indicate a long-term drug-free euglycemic remission in patients with newly diagnosed type 2 diabetes. The insulin dosage should be reduced even more quickly in the future treatment to decrease the potential harms

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call